Category:
Regulate Immune Function Preparations
CAS NO:
104987-11-3
Standard:
ChP,
For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was given FDA approval in 1994 for use in liver transplantation. Since then, this indication has expanded to kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis;
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients., , Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.